Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.45 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658991 | 0.98 | HPGD (0.57) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL12252175 | 0.91 | — | — | |
| SCHEMBL6360164 | 0.83 | EPHX2 (0.53) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL8848512 | 0.82 | EPHX2 (0.55) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL5645399 | 0.82 | EPHX1 (0.50) | EPHX1KMT2AEPHX2 | |
| SCHEMBL3303333 | 0.82 | HTT (0.43) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| SCHEMBL14045113 | 0.81 | HPGD (0.44) | HPGDEPHX1KMT2ARAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL7423753 | 0.80 | EPHX1 (0.49) | EPHX1EPHX2 | |
| SCHEMBL10274873 | 0.80 | KEAP1 (0.48) | EPHX1KMT2AKEAP1NFE2L2 | |
| SCHEMBL6359085 | 0.80 | KEAP1 (0.55) | HPGDEPHX1KMT2AEPHX2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2909201-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-08-26 | — | — | EP | claimed |
| WO-2014064038-A1 | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-01 | — | — | WO | claimed |
| EP-2463371-B1 | SIRNA CONJUGATE AND PREPARATION METHOD THEREOF | BIONEER CORP (KR) | 2015-08-26 | — | — | EP | disclosed |
| US-8410155-B2 | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-02 | — | — | US | disclosed |
| US-8334378-B2 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8084395-B2 | 4-aza indole derivatives and their use as fungicides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-8067438-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-8017771-B2 | Process for preparing acyclic HCV protease inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| US-20110177030-A1 | Hepatitis C Inhibitor Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-21 | — | — | US | disclosed |
| US-7939667-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2010-07-22 | — | — | US | disclosed |
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-10 | — | — | US | disclosed |
| US-7691868-B2 | N-{8-[2-chloro-5-(3-methylamino-prop-1-ynyl)-phenyl]-4,5-dihydro-thiazolo[4,5-h]quinazolin-2-yl}-acetamide; PI3-kinase modulators for the treatment of inflammatory or allergic diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20090124809-A1 | PROCESS FOR PREPARING ACYCLIC HCV PROTEASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-14 | — | — | US | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | LLINAS-BRUNET MONTSE | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145041-A1 | Thiazolyl-dihydro-quinazoline compounds and processes for preparing same | QDPR, NQO2, DHPS | HPGD 950/4885EPHX1 1722/4885KMT2A 3009/4885 |
| US-20120269769-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | HPGD 2635/4885EPHX1 1504/4885KMT2A 4209/4885 |
| US-20070243166-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | HPGD 2635/4885EPHX1 1504/4885KMT2A 4209/4885 |
| US-20090124809-A1 | PROCESS FOR PREPARING ACYCLIC HCV PROTEASE INHIBITORS | PREP, VIP, PEPD | HPGD 926/4885EPHX1 1048/4885KMT2A 2984/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | HPGD 872/4885EPHX1 2458/4885KMT2A 3930/4885 |
| US-20120034187-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | HPGD 2635/4885EPHX1 1504/4885KMT2A 4209/4885 |
| US-20110177030-A1 | Hepatitis C Inhibitor Compounds | HAVCR2, CTRL, CTRC | HPGD 2635/4885EPHX1 1504/4885KMT2A 4209/4885 |
| US-20100184598-A1 | 4-AZA INDOLE DERIVATIVES AND THEIR USE AS FUNGICIDES | IDO1, INMT, AZI2 | HPGD 958/4885EPHX1 1979/4885KMT2A 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.